Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

BD Launches New Research Tool to Study Cells Crucial in Cancer and Infectious Diseases

NextEdge Admin

27 Jun 2024

2 min 12 sec

BD (Becton, Dickinson and Company), a prominent global medical technology firm, has introduced advanced single-cell research tools aimed at enhancing scientists' understanding of cellular mechanisms underlying diseases like cancer. The newly launched BD Rhapsody™ ATAC-Seq Assay, part of BD's comprehensive single-cell multiomics solutions, facilitates epigenomic analysis at a single-cell level. This assay enables researchers to investigate how environmental factors influence DNA epigenetic changes within cells, crucial for unraveling disease mechanisms and developing targeted therapies.

BD's single-cell multiomics portfolio includes the BD Rhapsody™ TCR/BCR Next Multiomic Assay and BD Rhapsody™ Intracellular CITE-seq Assay, designed for the BD Rhapsody™ Single-Cell Analysis System. This system employs microwell-based technology, gentle on cells, ideal for intricate single-cell research. By offering a complete ecosystem of multiomics tools, including reagents and bioinformatics support, BD aims to empower researchers in academic, biopharmaceutical, and core lab settings to explore complex biological questions and accelerate advancements in precision medicine.

Steve Conly, worldwide president of Biosciences at BD, emphasizes that these innovations enable deep analysis of rare cells pivotal in diseases such as cancer and infectious diseases. BD's commitment extends to supporting healthcare providers and researchers worldwide, leveraging their extensive global presence and collaborative partnerships to address critical health challenges. Their solutions not only enhance clinical therapies and diagnostics but also improve laboratory capabilities for disease detection and therapeutic development.